Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Taste Disorders 1Parasomnias 1Pain 1Olfaction Disorders 1Neoplasms 1Nausea 1Marijuana Abuse 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Anxiety Disorders 1Anorexia 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Dronabinol × Clear all
NCT00316563 2010-02-09

Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

AHS Cancer Control Alberta

Phase 2 Completed
80 enrolled

Anorexia, Olfaction Disorders, Neoplasms, Taste Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡